ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) plus E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)
Article
Motzer, R. J.; Lee, C-H.; Emamekhoo, H.; Matrana, M.; Percent, I.; Hsieh, J. J.; Hussain, A.; Vaishampayan, U. N.; Graham, R.; Liu, S.; McCune, S.; Shaheen, M.; Parmar, H.; Shen, Y.; Whiting, S. H.; Tannir, N. M.
